A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.
Ages Eligible for Study: 12 months to 21 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Open and Recruiting
This study is currently recruiting participants.